The Prevalence of Cardiovascular Comorbidity in COVID-19 at West Nusa Tenggara General Hospital from March to December 2020

DOI

10.2991/ahsr.k.220206.003How to use a DOI?

Keywords

COVID-19; cardiovascular disease; comorbidity; case fatality rate

Abstract

The SARS-CoV-2 virus as the cause of COVID-19 has been declared a pandemic since March 2020. The clinical signs of COVID-19 are heterogeneous, such as 20–51% of patients were accounted have at least one comorbidity, with diabetes melitus (10–20%), hypertension (10–15%) and other cardiovascular and cerebrovascular complications (7–40%). This was a descriptive retrospective research design that collected data from all patients with COVID-19 at West Nusa Tenggara General Hospital, Mataram, Indonesia This study is approved by the ethics committee of the West Nusa Tenggara Hospital. We compiled the clinical data from medical record. The COVID-19 diagnosis and CVD diagnosis was made based on ICD X. Statistical analyses were conducted with Microsoft Excel. Of the 826 cases, 84 (10%) reported having CVD comorbidity. The prevalence of specific CVD according to ICD X was: hypertension (n=50, 6%), coronary artery disease (n=10, 1.21%), congestive heart failure (n=10, 1.21%), hypertensive disease with heart failure (n=4, 0.5%), hypertensive disease without heart failure (n=4, 0.50%), secondary hypertension due to endocrine disorders (n=1, 0.12%), renal hypertension with renal failure (n=1, 0.12%), complete atrioventricular block (n=1, 0.12%), ischemic cardiomyopathy (n=1, 0.01%), left bundle branch block (n=1, 0.12%), sick sinus syndrome (n=1, 0.12%). Case fatality rate was 1.2%. On the other hand, information from the China’s national health commission reports that 35% have comorbid hypertension and 15% have coronary heart disease. Case fatality rate in patients with comorbid heart disease is reported to be 6% in hypertension and 10.5% in heart disease. This mechanism is related to the increased expression of angiotensin-converting enzyme which is bind to the corona virus. Among patients with CVD comorbidity have a higher risk of COVID-19. A thorough assessment of comorbidities might assist to establish the risk of patients at hospital admission.

Copyright

© 2022 The Authors. Published by Atlantis Press International B.V.

Open Access

This is an open access article under the CC BY-NC license.

Download article (PDF)

TY  - CONF
AU  - Yusra Pintaningrum
AU  - Imam Fadhullah Pratama
PY  - 2022
DA  - 2022/02/21
TI  - The Prevalence of Cardiovascular Comorbidity in COVID-19 at West Nusa Tenggara General Hospital from March to December 2020
BT  - Proceedings of the 2nd Global Health and Innovation in conjunction with 6th ORL Head and Neck Oncology Conference (ORLHN 2021)
PB  - Atlantis Press
SP  - 11
EP  - 13
SN  - 2468-5739
UR  - https://doi.org/10.2991/ahsr.k.220206.003
DO  - 10.2991/ahsr.k.220206.003
ID  - Pintaningrum2022
ER  -